Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

Prostate Cancer Clinical Trial

— vit D & PCa  

Official title:

Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00953225
• Other study ID #: CLIN-004-09S
• Secondary ID: MUSC IRB HR#1934
• Status: Completed
• Phase: Phase 2
• First received: August 4, 2009
• Last updated: September 8, 2017
• Start date: January 7, 2010
• Est. completion date: October 30, 2014

Study information

• Verified date: September 2017
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical prostate cancer to clinical disease. The investigators propose to conduct a clinical study aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans diagnosed with low-risk, early-stage prostate cancer, who elect to have their disease monitored through active surveillance. The successful completion of this proposed clinical study will allow us to determine whether correcting vitamin D deficiency in Veterans diagnosed with early-stage prostate cancer will prevent progression of their disease and improve their prognosis.

Description:

Vitamin D promotes the differentiation of prostate cancer (PCa) cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical PCa to clinical disease. These considerations support the use of vitamin D3 as a chemopreventive agent.

We hypothesize that a daily dose of vitamin D3 (4,000 IU) taken for one year by Veterans diagnosed with low-risk, early-stage PCa, who are eligible for active surveillance will: a) result in a measurable decrease of serum PSA levels in a significant number of enrolled subjects, and b) be associated with a stabilization or improvement of their PCa pathology, as assessed through histological examination of prostate tissue biopsy specimens (Gleason score and percent of positive biopsies) obtained at the end of the study, as part of their standard medical care for active surveillance.

This VA Merit application proposes to conduct a randomized, placebo-controlled clinical study aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans diagnosed with early-stage prostate cancer, who elect to have their disease monitored through active surveillance (before considering definitive therapy). The main objectives of this proposed clinical study are as follows:

1. To determine whether a daily supplement of 4,000 IU of vitamin D3 taken for twelve months will result in a measurable and significant decrease of serum PSA levels in Veterans diagnosed with low-risk, early stage PCa (Gleason score 6, PSA 10, clinical stage T1C or T2a), who elect to have their disease monitored through active surveillance for at least one year.

2. To determine in enrolled Veterans the pathology status of their PCa by analyzing prostate tissue biopsy specimens at the end of the study (Gleason score and percentage of positive biopsies), and by comparing them with those obtained before enrollment in this study, as part of their standard medical care.

The implementation of these proposed studies will allow us to assess whether vitamin D3 supplementation can be utilized as a chemopreventive regimen in Veterans diagnosed with low-risk, early stage PCa, and provide a useful addition to active surveillance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: October 30, 2014
• Est. primary completion date: December 15, 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 19 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male Veterans (> 18 years of age) recently diagnosed with low-risk PCa (histologically documented adenocarcinoma of the prostate)

• A serum PSA value of up to 10.0 ng/ml, and a Gleason score of six or less (three or less in either architectural pattern)

• For the purpose of eligibility, these additional criteria will be verified: *serum creatinine 2.0 mg/dL

• serum phosphate (measured as phosphorus) > 2.3 and < 4.8 mg/dL

• serum calcium > 8.5 and < 10.5 mg/dL

Exclusion Criteria:

• Subjects with any concurrent malignancy, except non-melanoma skin cancer

• Subjects with a history of sarcoidosis

• Subjects with a history of high-dose (1,000 IU per day) vitamin D supplementation

• Subjects with a history of hypercalcemia

• Subjects who use lithium as a medication

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• vitamin D3
4,000 IU daily for one year
• Placebo daily for one year
Placebo

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Ralph H. Johnson VA Medical Center, Charleston, SC	Charleston	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
VA Office of Research and Development	Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PSA Slope (Trajectory) or the Change in PSA Level Over Time	Change in PSA (ng/mL) from baseline to 1 year visit, which include the baseline through 1 year follow-up.	1 year (visits # 1-8)
Secondary	Number of Positive Biopsy Cores (Out of Twelve) Compared to the Corresponding Values Assessed Before Enrollment	Change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation.	1 year